000 04020cam a2200565 i 4500
001 1411033330
003 OCoLC
005 20250131161814.0
006 m o d
007 cr |||||||||||
008 230517s2023 nju ob 001 0 eng
020 _a9781119824572
_q(ebook)
020 _a1119824575
020 _a9781119824558
_q(adobe pdf)
020 _a1119824559
020 _a9781119824565
_q(epub)
020 _a1119824567
020 _z9781119824541
_q(hardback)
035 _a(OCoLC)1411033330
040 _aDLC
_beng
_erda
_cDLC
_dOCLCO
_dDG1
042 _apcc
050 0 0 _aRC280.L9
060 0 0 _aWH 525
245 0 0 _aImmunologic approaches for the treatment of lymphoid malignancies :
_bfrom concept to practice /
_cedited by Owen A. O'Connor, Stephen M. Ansell, John Gribben
264 1 _aHoboken, NJ :
_bWiley Blackwell
_c2023
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
490 1 _aPrecision cancer therapies ;
_vvolume 2
504 _aIncludes bibliographical references and index
520 _a"Optimizing an effective antitumor immune response has always been the goal of immunological strategies to treat cancer. It has been known for many years that the immune system plays a central role in cancer development and control; and promoting the immune response may be of profound therapeutic value. Patients with evidence of immunosuppression are at higher risk for cancer and while spontaneous remissions in certain cancers are uncommon, they are a well-recognized phenomenon. Additionally, there are reports of patients whose malignancy regressed at the time of an infectious episode suggesting that activation of the immune system promoted an anti-tumor effect. Furthermore, many indolent lymphomas follow a 'waxing and waning' course suggesting that the immune system may modulate progression of the disease. Understanding the components of an effective antitumor immune response, and developing strategies to optimize them, has led to remarkable advances in the treatment of cancer, particularly lymphoid malignancies. Some of the key steps in this process are highlighted below and the various components of immunotherapy in use to treat patients are discussed in the chapters that follow"--
_cProvided by publisher
506 _aAvailable to OhioLINK libraries
650 0 _aCellular immunity.
_0https://id.loc.gov/authorities/subjects/sh85021695
650 1 2 _aLymphoma
_ximmunology.
_0https://id.nlm.nih.gov/mesh/D008223Q000276
650 1 2 _aLymphoma
_xtherapy.
_0https://id.nlm.nih.gov/mesh/D008223Q000628
650 2 2 _aImmunotherapy
_xmethods.
_0https://id.nlm.nih.gov/mesh/D007167Q000379
650 2 2 _aImmunoconjugates
_xtherapeutic use.
_0https://id.nlm.nih.gov/mesh/D018796Q000627
650 2 2 _aImmunity, Cellular.
_0https://id.nlm.nih.gov/mesh/D007111
_9144365
700 1 _aO'Connor, Owen A.,
_0https://id.loc.gov/authorities/names/n2020184152
_eeditor
_9143678
700 1 _aAnsell, Stephen M.,
_0https://id.loc.gov/authorities/names/no2008027310
_eeditor
700 1 _aGribben, John,
_0https://id.loc.gov/authorities/names/n99044558
_eeditor
710 2 _aOhio Library and Information Network.
_0https://id.loc.gov/authorities/names/no95058981
776 0 8 _iPrint version:
_tImmunologic approaches for the treatment of lymphoid malignancies
_dHoboken, NJ : Wiley Blackwell 2023
_z9781119824541
_w(DLC) 2023023583
830 0 _aPrecision cancer therapies ;
_0https://id.loc.gov/authorities/names/n2022184659
_vv. 2
856 4 0 _3OhioLINK
_zConnect to resource
_uhttps://rave.ohiolink.edu/ebooks/ebc2/9781119824572
856 4 0 _3Wiley Online Library
_zConnect to resource
_uhttps://onlinelibrary.wiley.com/doi/book/10.1002/9781119824572
856 4 0 _3Wiley Online Library
_zConnect to resource (off-campus)
_uhttps://go.ohiolink.edu/goto?url=https://onlinelibrary.wiley.com/doi/book/10.1002/9781119824572
999 _c200463874
_d82086